Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trialJoaquı́n Mateo, Johann S. de Bono, Daniel Nava Rodrigues et al.|The Lancet Oncology|2019Cited by 643
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP InhibitionJane Goodall, Johann S. de Bono, Joaquı́n Mateo et al.|Cancer Discovery|2017Cited by 422
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancerDaniel Nava Rodrigues, Charles G. Drake, Pasquale Rescigno et al.|Journal of Clinical Investigation|2018Cited by 209
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B TrialSuzanne Carreira, Johann S. de Bono, Núria Porta et al.|Cancer Discovery|2021Cited by 161
Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)Jonathan Welti, Johann S. de Bono, Adam Sharp et al.|Clinical Cancer Research|2018Cited by 158